A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Pazopanib (Primary) ; Paclitaxel
- Indications Urogenital cancer
- Focus Therapeutic Use
- Acronyms PLUTO
- 12 Apr 2017 Results published in the Journal of Clinical Oncology.
- 10 Jan 2015 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
- 08 Nov 2014 Accrual to date is 93% according to United Kingdom Clinical Research Network record.